Stockreport

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results

Pliant Therapeutics, Inc.  (PLRX) 
PDF Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Enrollment continues in BEACON-IPF, a Phase 2b trial [Read more]